Bayer's eliapixant hits the right notes in PAGANINI cough st...

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant.

Chasing Merck & Co, Bayer builds case for cough drug eliapix...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval i

COVID cough app Hyfe launches in UK and Ireland

A smartphone app that uses artificial intelligence to assess the sound of coughing has been launched in the UK, and according to its developer could be an early warning system for COVID-19

Does my cough sound like COVID? There could be an app for th...

It could be possible to detect whether someone has COVID-19 or not, just from the sound of their coughing.

Merck & Co plans to file cough drug gefapixant after phase 3...

Merck & Co is planning to file a drug for unexplained or treatment-resistant cough after supportive results from two phase 3 trials.

Merck’s chronic cough drug gefapixant clears phase 3 test